Technology, makes health simpler
Mature platform technology Customized product services
End-to-end independent manufacturing
Technology, makes health simpler
Mature platform technology Customized product services
End-to-end independent manufacturing
-
Statement
To safeguard the brand image of ENJOSIM Medical and protect the legitimate rights and interests of consumers and partners, Shanghai Enjosim Medical Technology Co., Ltd. and its wholly-owned subsidiary, Jiangsu Enjosim Medical Technology Co., Ltd., hereby issue this solemn statement:
넶29 2025-09-07 -
英捷信医疗一次性注射笔药包材项目获批上市
近日,英捷信医疗迎来重要发展里程碑:公司申报的两款一次性笔式注射器(登记号:B20240000588、B20240000552,对应规格 YJXYC-06C01、YJXYC-06C02),经国家药品监督管理局药品审评中心(CDE)审批,正式由 “I” 状态变更为 “A” 状态,成功获批上市。这一项目的获批,标志着公司在自我给药系统领域实现 “器械 + 药包材” 全链条合规布局,为国产高端医疗器械创新发展注入强劲新动能。
넶15 2026-04-10 -
聚焦生物产业开年首展,英捷信医疗邀您共探注射给药未来(BIOCHINA 2026)
2026年3月12-14日,第十一届易贸生物产业展览(BIOCHINA 2026)将在苏州国际博览会拉开帷幕。
넶70 2026-03-03
ABOUT US
ENJOSIM MEDICAL specializes in the research, development, and manufacturing of high-precision drug delivery devices. Its product portfolio includes delivery systems for biologics such as insulin, GLP-1, and growth hormone, with an annual production capacity of nearly 100 million injection pens. The company operates a 16,000m² modern facility equipped with three fully automated MIKRON assembly lines, featuring Class 100,000 GMP-compliant cleanrooms, precision injection molding workshops, and an in-house mold manufacturing center, This supports a vertically integrated production system that covers product design, mold development, precision molding, and automated assembly. The company has secured six domestic medical device registration certificates, and achieved ISO 13485:2016 and MDSAP certifications.Its products hold EU CE certification, Canada MDL, India CDSCO registration, Brazil ANVISA registration, and an FDA DMF number. Based on the outstanding R&D capabilities, extensive experience in combination product registration, and strict medical device quality management system, the company has completed multiple rounds of strategic financing and established in-depth partnerships with numerous global biopharmaceutical leaders.The company is committed to providing high-quality drug delivery devices to the global biopharmaceutical industry through continuous innovation, promoting the development of precision medicine.
Production capacity
Injection pen model
Mikron automation assembly line
Core patents
SimTouch Pen
Matching Biologic Agents
Semaglutide,Tirzepatide,Liraglutide,Insulin,HGH,FSH etc
Disposable Prefilled Injection Pen
Matching Biologic Agents
Semaglutide,Tirzepatide,Liraglutide,Insulin,HGH,FSH etc
Two-step Auto Injector
Matching Biologic Agents
Semaglutide, Tirzepatide, Auto - Immune Biological Agents etc
Address :
Room 505, No.1B Building,No.800 Qingdai Road, Pudong New Area, Shanghai,China
Email:
sales@jsenjosim.com
-
ꁸ Top
-
ꂅ 88888888
-
ꀥ QR code
